INTRODUCTION
============

Adaptive and innate immune responses represent the most powerful tool used by the host to counteract infectious agents. Additional intrinsic defense systems against viral infections have been recently identified. They include host-encoded restriction factors, initially described for their inhibitory effect on immunodeficiency virus type 1 (HIV-1) infection (reviewed in [@B128]), such as apolipoprotein B mRNA-editing catalytic polypeptides (APOBECs; [@B108]; [@B17]; [@B97]), TRIM (tripartite motif) family members ([@B117]; [@B89]; [@B30]), tetherin ([@B84]; [@B58]), and sterile alpha motif (SAM) and HD domain-containing protein 1 (SAMHD1) ([@B60]; [@B107]). Most of these anti-viral proteins were uncovered through the discovery of viral factors that counteract their function, implying that viruses are resistant to the restriction factors of their natural hosts. Although these findings suggested a cross-species restriction, further studies demonstrated that restriction factors may limit pathogenicity *in vivo* even in their specific host (reviewed in [@B101]). Besides HIV, the phenomenon of viral restriction has been investigated in other viral infections including oncogenic human T cell lymphotropic virus type 1 (HTLV-1) infection. HTLV-1 was the first human oncogenic retrovirus to be discovered ([@B94]). HTLV-1 is closely related to the less pathogenic HTLV-2 virus. The genomes of these viruses code for similar structural, enzymatic, and regulatory proteins ([@B33]; [@B85]). Among them, the transcriptional activators, named Tax-1 (HTLV-1) and Tax-2 (HTLV-2) share roughly 77% amino acid sequence homology and have conserved functional regions. Both viruses infect primarily T lymphocytes, but their infection is associated with different disease manifestations. HTLV-1 is the etiologic agent of an aggressive form of adult T cell leukemia/lymphoma (ATLL), of a neurological disorder designated HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and inflammatory disorders ([@B136]; [@B126]; [@B71]). Tax-1 plays a major role in the onset of leukemogenesis by regulating cell cycle progression, cell growth, apoptosis, and DNA repair ([@B29]; [@B41]; [@B54]; [@B76]; [@B134]). HTLV-2 has been linked to HAM/TSP "like" cases, whereas no clear epidemiological link to lymphoproliferative malignancies has been demonstrated ([@B64]; [@B103]). Comparative studies of Tax-1 and Tax-2 functions brought to light major phenotypic differences in their viral transactivating capacity, transforming activity, modulation of cellular genes expression, and subcellular localization ([@B106]; [@B118]; [@B26]; [@B111]; [@B110]; [@B8]; [@B100]; [@B124]).

Studies on the role of restriction factors in HTLV-1 infection are controversial. HTLV-1 replicates in the same cells as HIV-1 and it does not express an accessory protein analogous to HIV-1 Vif that inactivates hAPOBEC3G. Nevertheless, HTLV-1 seems to be relatively resistant to hAPOBEC3 proteins ([@B73]; [@B87]). [@B21] have shown that resistance of HTLV-1 to hAPOBEC3G is mediated by the C-terminus of gag, which seems to exclude hAPOBEC3G from virions. Other reports have shown that hAPOBEC3G is packaged into HTLV-1 particles, but with opposite effects on virion infectivity ([@B83]; [@B104]). Interestingly, it has been hypothesized that non-sense mutations in viral genes induced by hAPOBEC3G might allow the virus to escape the host immune response ([@B28]). Studies related to a possible effect of tetherin on HTLV-1 infectivity indicated that tetherin reduces cell-free infectivity of HTLV-1 with a minor effect on cell-to-cell transmission ([@B45]). Finally, evidence of HTLV-1 resistance to SAMHD1-mediated restriction have been recently reported ([@B38]).

Another cellular protein with anti-viral function is the MHC class II (MHC-II) transactivator, also designated CIITA (class II transactivator). The gene encoding CIITA and the elucidation of its function as the master regulator of MHC-II gene transcription and, thus, of antigen presentation to CD4^+^ T helper cells (TH) were first discovered in our laboratory ([@B3]). Upon antigen recognition TH cells coordinate both humoral and cellular immune responses to eradicate pathogen infections and fight tumors ([@B5]). This prominent role of CIITA in the homeostasis of the immune system has emerged from the elucidation of the molecular defect at the basis of the bare lymphocyte syndrome (BLS), a severe form of combined immunodeficiency, characterized by the loss of expression of MHC-II molecules ([@B133]; [@B116]; [@B98]). CIITA is a protein of 1130 amino acids localized in both the nucleus and the cytoplasm; it contains four functional domains: the N-terminal transcription activation domain (AD); the proline/serine/threonine-rich region (P/S/T); the GTP-binding domain (GBD), and the C-terminal leucine-rich repeats (LRR) that are critical for the subcellular distribution of the protein ([@B19]). The integrity of CIITA domains is critical for the activation function on the MHC-II promoter. CIITA regulates MHC-II gene expression by coordinating sequential steps of the transcription process from the assembly of the general transcriptional machinery and the recruitment of coactivators and chromatin remodeling factors, to the binding of transcription elongation factors ([@B31]). CIITA is recruited to MHC-II promoters via the interaction with DNA-bound factors including the regulatory factor X (RFX) complex and the trimeric NF-Y complex ([@B12]; [@B22]; [@B75]; [@B139]; [@B46], [@B47]). Both constitutive and IFNγ-inducible expression of MHC-II is controlled by CIITA, whose gene is regulated at transcriptional level by three distinct promoters driving CIITA expression in different cell lineages ([@B99]).

Several years ago, we discovered that CIITA restricts HIV-1 infection by acting at the level of viral replication. The molecular mechanism at the basis of this inhibition is the competition between CIITA and HIV-1 Tat transactivator for the cyclin T1 subunit of the elongation complex P-TEFb (positive transcription elongation factor b; [@B4]). In this review we summarize our knowledge of the role of CIITA as a restriction factor for HTLV-1 and HTLV-2 viruses. We discuss the results on the inhibition of Tax-1 and Tax-2 functions by CIITA and concentrate on novel insights into the mechanisms through which CIITA operates this suppressive function.

CIITA INHIBITS BOTH HTLV-1 AND HTLV-2 VIRAL REPLICATION
=======================================================

Beside inhibiting HIV-1 transcriptional elongation, CIITA inhibits also the replication of HTLV-1 and HTLV-2. As far as HTLV-1, we demonstrated that exogenously expressed CIITA in 293T cells transfected with the HTLV-1 molecular clone pACH resulted in strong inhibition of HTLV-1 virus production. More importantly, in promonocytic cells endogenously expressed CIITA produced the same effect ([@B121]). Two phenotypically and functionally distinct clones of the promonocytic U937 cell line, named *Minus* and *Plus,*previously characterized for their inefficient or efficient capacity to support productive HIV-1 infection, respectively ([@B34]), were studied. Interestingly, we found that the *Minus* clone expresses CIITA and MHC-II, whereas the *Plus* clone does not express either. *Minus* and*Plus* clones were transfected with the pACH plasmid and assessed for viral expression by measuring p19 antigen in the cell supernatants. Remarkably, and similarly to what observed with the HIV-1 infection, we found that the two clones had a different behavior with respect to HTLV-1 infection. The p19 levels were drastically reduced in the supernatants of CIITA-positive *Minus* clone, compared with the CIITA-negative *Plus* clone. Moreover, the stable expression of CIITA in the *Plus* clone after transfection with CIITA cDNA, reverted its permissive phenotype to the *Minus*-like non-permissive one (**Figure [1A](#F1){ref-type="fig"}**), demonstrating that CIITA is a major restriction factor for HTLV-1. As far as HTLV-2 infection, we found that cells of both the T- and B-lineage are less permissive to HTLV-2 replication in the presence of CIITA. In particular, by using the isogenic B cell system, consisting of CIITA-positive Raji cells and its CIITA-negative derivative RJ.2.2.5 ([@B1]), it was found that RJ.2.2.5 sustained very high levels of virus replication, whereas a profound inhibition of viral replication was observed in Raji parental cells, although both cell lines were equally infected by HTLV-2. Thus, physiologic levels of CIITA were able to strongly inhibit HTLV-2 expression. Consistent with this observation, the permissive RJ2.2.5 cells stably transfected with CIITA cDNA became refractory to HTLV-2 replication showing almost undetectable levels of p19 antigen upon viral infection ([@B14], **Figure [1B](#F1){ref-type="fig"}**).

![**Endogenous CIITA inhibits both HTLV-1 and HTLV-2 gene expression.** **(A)** CIITA-negative U937 *plus* clone, CIITA-positive U937 *minus* clone, and U937 *plus* clone stably expressing fCIITA (U937 *plus* fCIITA) were transfected with the pACH plasmid containing the entire HTLV-1 genome. The amount of HTLV-1 p19 antigen (pg/ml) in cells supernatants was detected by enzyme-linked immunoassay (ELISA) 48 h post-transfection. Error bars indicate standard deviations. Derived from [@B121]. **(B)** CIITA-positive Raji cells, their CIITA-negative isogenic mutant RJ2.2.5, and the RJfCIITA cells stably transfected with CIITA were infected with the HTLV-2 Gu strain 2b and the productive infection was evaluated by the presence of HTLV-2 p19 antigen (pg/ml) in cell culture supernatants measured by (ELISA). Error bars indicate standard deviations. Derived from [@B14].](fmicb-04-00234-g001){#F1}

Overall, our observations indicated that physiologic amounts of CIITA may inhibit viral expression in cells that are natural target of HTLV-1 and HTLV-2 infection, suggesting that *in vivo* the virus may replicate preferentially in cells lacking CIITA. In this regard, it is interesting that during dendritic cell (DC) maturation induced by different stimuli (LPS, CD40L, Sendai virus, *Salmonella* typhimurium, IFNα, and TNFα), the expression of MHC-II molecules is increased due to an enhanced transport of preformed molecules to the cell surface. In contrast*, de novo* biosynthesis of MHC-II mRNA is shut off because of the epigenetic silencing of CIITA gene ([@B62]). Thus, it is conceivable that a similar CIITA silencing might occur in DC infected by HTLV-1 allowing viral replication and spreading to CD4^+^ T cells ([@B51]).

CIITA TARGETS Tax-1 AND Tax-2 TRANSACTIVATORS TO INHIBIT VIRAL EXPRESSION
=========================================================================

In searching for the molecular mechanisms through which CIITA inhibits HTLV-1 and HTLV-2 viral replication, we found that CIITA targets the viral transactivators Tax-1 and Tax-2. Indeed, we showed that exogenous CIITA could inhibit the Tax-1- and Tax-2-mediated HTLV LTR transactivation in LTR-driven luciferase gene reporter assays ([@B14]; [@B123], [@B121]; [@B88]). By using several CIITA deletion mutants, the N-terminal region 64--144 was found to be minimally necessary to inhibit both Tax-1 and Tax-2 function (**Figure [2](#F2){ref-type="fig"}**).

![**Schematic representation of CIITA regions involved in the suppression ofTax function and in CIITA-Tax association.** At the top is a diagram of CIITA with its domains: AD, activation domain; P/S/T, proline/serine/threonine-rich domain; GBD, GTP-binding domain; and LRR, leucine-rich repeats. The black box represents the minimal domain from positions 64--144 that is necessary to block the transcription function of Tax (*Tax-inhibition*, middle). Hatched (positions 1--252) and gray (positions 253--410) boxes represent the two regions of CIITA interacting with Tax (*Tax interaction*, bottom).](fmicb-04-00234-g002){#F2}

Accordingly, HTLV-2 replication was found to be strongly suppressed in RJ.2.2.5 B cells stably transfected with the N-terminal 1--321 fragment of CIITA, which localizes mostly in the nucleus. In contrast, the cytoplasmic mutant CIITA 322--1130, which does not contain the minimal inhibitory domain, did not significantly inhibit HTLV-2 expression ([@B123]).

Similarly, cytoplasmic CIITA mutants containing the region 64--144 and partially and /or temporarily accumulating in the nucleus, inhibited Tax-1 transactivation. This was observed with a mutant having the internal deletion of the region 253--410 mediating dimerization of CIITA ([@B122]) and accumulating in the nucleus after treatment with Leptomycin B (LMB), an inhibitor of CRM1-mediated nuclear export. Importantly, the study of this mutant in relation to Tax-1 inhibition, provided new insights on the cellular biology of CIITA. For the first time, phosphorylation-dependent dimerization of CIITA has been defined as a critical post-translational modification (PTM) required for CIITA nuclear retention and, thus, transcriptional activity on MHC-II promoters ([@B121]). However, because full length CIITA has a dual nuclear and cytoplasmic localization, our findings do not exclude that CIITA might also inhibit Tax in the cytoplasm. Studies are in progress to assess whether cytoplasmic CIITA mutants containing the N-terminal inhibitory region, still inhibit Tax. These experiments will clarify whether CIITA exerts its suppressive function on Tax in both the nucleus and the cytoplasm, potentially revealing a more complex picture, as CIITA might exploit distinct molecular mechanisms to inhibit Tax in the two cellular compartments.

This will be particularly relevant for Tax-2, which, differently from Tax-1, exhibits a predominant cytoplasmic distribution with some accumulation in nuclear bodies ([@B77]; [@B109]; [@B125]).

A relevant finding of our studies, instrumental in understanding the complex picture of the CIITA-mediated inhibition of Tax-1 and Tax-2 function, was the demonstration of the *in vivo* molecular interaction between CIITA and Tax-1/Tax-2 ([@B88]; [@B121]). Since CIITA is localized predominantly in the nucleus but also to a lesser extent in the cytoplasm, one possible scenario is that the cytoplasmic fraction of CIITA could bind Tax itself or a cellular factor crucial for Tax transactivation, inhibiting their nuclear translocation. Intriguingly, our interaction studies revealed that CIITA associates *in vivo* with Tax-1 and Tax-2 by using two adjacent regions at the N-terminus (**Figure [2](#F2){ref-type="fig"}**). The region 1--252 mediates both the binding to the transactivators and their functional inhibition, whereas the region 253--410 binds to, but does not inhibit Tax proteins ([@B88]; [@B121]). We suggested that the two regions form a single Tax-interacting surface in the context of the entire CIITA molecule, but only the presence of the minimal domain 64--144 confers inhibitory properties to this association. Tax-1 region involved in this interaction spans amino acids sequence 1 to 108, including the CREB (cAMP response element-binding protein)-binding domain ([@B6]; [@B37]; [@B121]). In searching for similar or distinct mechanisms of CIITA-mediated inhibition of Tax-1 and Tax-2, future experiments will assess whether CIITA binds the same N-terminal region of Tax-2. Of note, CIITA-Tax interaction was not observed with proteins produced *in vitro* (data not shown) indicating that a bridging cell factor might play a role in this interaction or that PTM, that do not occur *in vitro*, are crucial to promote the binding. Many studies have shown that sumoylation, ubiquitination, acetylation, and phosphorylation play a critical role in the subcellular localization, protein--protein interaction and function of both Tax-1 and Tax-2, revealing similarities and differences between the two transactivators ([@B9]; [@B16]; [@B61]; [@B24]; [@B82]; [@B36]; [@B69]; [@B125]; [@B10]; [@B8]; [@B52]). In addition, dimerization of Tax-1 is necessary for its nuclear localization and interaction with CREB and the 21-bp repeat elements ([@B119]; [@B50]; [@B7]; [@B35]). Similarly, we previously described that CIITA expressed in cells, but not CIITA produced *in vitro*, forms homodimers in a phosphorylation-dependent manner ([@B122]) and this modification is a prerequisite to CIITA nuclear retention ([@B121]). Nevertheless, the inability of CIITA to interact with Tax *in vitro* cannot be ascribed to the incapacity of CIITA to self-associate *in vitro*, because, as mentioned above, the dimerization-deficient CIITAΔ253--410 mutant retains the ability to inhibit Tax-1 *in vivo*. Other modifications of CIITA, including acetylation, deacetylation, and ubiquitination ([@B115]; [@B131] and references therein), might have a major role in Tax-1-binding. Such PTMs have been reported to affect the interaction of CIITA with cellular factors involved in MHC-II transcription ([@B40]) and the recruitment of either corepressors or coactivators on different promoters ([@B132]; [@B131]). PTMs-defective forms of both Tax and CIITA will be crucial to determine the potential role of specific modification in Tax-binding and/or functional inhibition. For instance, we have evidence that Tax-1 interacts with both the hypo- and the hyper-phosphorylated forms of CIITA (data not shown).

Overall, our findings suggest that CIITA-mediated inhibition of Tax activity could rely on the physical association between the two factors. We know that this binding occurs off DNA, but it is still unclear whether Tax--CIITA complexes are recruited on the HTLV LTR (**Figure [3A](#F3){ref-type="fig"}**). If this were case, two hypotheses are equally plausible. Tax bound to CIITA is not assembled on the viral promoter and this correlates with the inhibition of Tax-mediated LTR activation (**Figure [3B](#F3){ref-type="fig"}**). Alternatively, the binding of CIITA to Tax could still permit its recruitment on the LTR, but not its transcription function. CIITA might prevent the interaction of Tax with components of the transcriptional machinery required for HTLV LTR transactivation (**Figure [3C](#F3){ref-type="fig"}**). In this context, it is intriguing that, as discussed below, the direct interaction of Tax-1 with PCAF (P300/CBP-associated factor), which cooperates with Tax-1 to activate transcription from the LTR ([@B49]), is severely impaired in the presence of CIITA ([@B121]). To discriminate between the two above hypotheses, ChIP/EMSA assays are required. However, our subcellular distribution studies of Tax proteins in the presence of CIITA seem to favor the first mechanism. Tax-2 colocalizes with CIITA in the cytoplasm with a characteristic accumulation around the nuclear membrane potentially contributing to Tax-2 loss of function. Interestingly, Tax-2 does not respond by itself to LMB treatment ([@B15]); however, in cells treated with LMB, CIITA recruits Tax-2 into the nucleus ([@B88]). This suggests that CIITA exerts a driving force on Tax-2 distribution. More recently, extending these studies to Tax-1, we have shown that untagged Tax-1 expressed in 293T cells is trapped by CIITA in the cytoplasm of the majority of cells (Tosi et al., manuscript in preparation). Similarly to Tax-2, the impaired shuttling of Tax-1 into the nucleus, may account for the functional inhibition of Tax-1 by CIITA.

![**CIITA-Tax interaction might differently affectTax-mediated activation of the viral LTR promoter.** **(A)** In the absence of CIITA, Tax-1 is recruited by CREB to the viral LTR and promote the formation of an higher order multiprotein complex activating transcription. **(B)** CIITA binds Tax and prevents its recruitment to the LTR promoter. **(C)** Tax bound to CIITA is recruited to the LTR, but its transcription function is impaired.](fmicb-04-00234-g003){#F3}

Tax AND CIITA USE COMMON CELLULAR FACTORS TO CONTROL TRANSCRIPTION OF THEIR TARGET PROMOTERS
============================================================================================

Tax interacts with a multitude of cellular factors, forming the so called Tax interactome, to modulate the expression of viral and host genes ([@B11]; [@B112]). Most of these physical and functional interactions derive from studies on HTLV-1 Tax-1. Much less is known about the cellular partners mediating Tax-2 biological functions. Notably, many of these Tax-interacting cellular proteins are used also by CIITA to activate the transcription of MHC-II promoters. These commonly utilized factors include transcriptional modulators, chromatin modifying enzymes, basal transcription factors, and transcription elongation factors (**Table [1](#T1){ref-type="table"}**).

###### 

Physical and functional interaction shared by Tax and CIITA.

  Proteins    Function                           Reference
  ----------- ---------------------------------- -------------------------------------------------------
  CREB        Transcriptional activators         [@B59], [@B121], [@B80], [@B68], [@B139].
  NF-YB                                          [@B93], [@B121], [@B88], [@B47], [@B139], [@B75].
  TFIID       Basal transcription factors        [@B13], [@B31].
  CBP, p300   Chromatin remodeling factors       [@B43], [@B42], [@B56], [@B3], [@B1], [@B57], [@B32].
  PCAF                                           [@B49], [@B123], [@B121], [@B115]
  HDAC1                                          [@B27], [@B65], [@B70], [@B142].
  BRG1                                           [@B130] [@B25], [@B137], [@B81].
  CARM1                                          [@B48], [@B141].
  P-TEFb      Transcription elongation factors   [@B138], [@B18], [@B53].

In addition, Tax and CIITA share several functional features. Neither are classical DNA-binding transcription factors, but instead interact with a platform of DNA-bound proteins to be recruited to the target promoters. Among them, CREB plays a major role promoting the formation of a multiprotein complex on DNA required for the full transcriptional activation ([@B59]; [@B80]; [@B139]; [@B68]). In particular, Tax interaction with CREB docked at CRE sites of the viral 21-bp repeats, stabilizes the formation of the ternary complex and recruits the coactivators CBP/p300 and PCAF ([@B43], [@B42]; [@B56]; [@B49]). Another transcription factor that interacts with both Tax and CIITA, is the B subunit of the NF-Y complex, which binds the inverted CCAAT sequence in the Y-box of MHC-II promoters ([@B93]; [@B75]; [@B139]; [@B47]). While many investigations had assessed the contribution of NF-Y to class II transcription, no data regarding the specific role of NF-Y in HTLV transcription were available until recently. We confirmed the association between NF-YB and Tax-1 and extended it to the Tax-2 transactivator, which binds both to transfected and endogenous NF-YB in 293T cells ([@B88]; [@B121]). For the first time we have shown that the over-expression of NF-Y significantly inhibited Tax-2-driven, but not Tax-1-driven LTR transactivation ([@B123], [@B121]). The reasons for this discrepancy are presently unknown and require further investigation. These findings, however, do not conclusively address how endogenous NF-Y might be important for modulating Tax transactivation capacity. It must be stressed that NF-Y is an ubiquitous factor and, seemingly, its physiologic levels do not impair Tax-2 transcriptional activity, as demonstrated by our Tax-dependent gene reporter assays performed in 293T/COS cells and by HTLV-2 productive infection of RJ.2.2.5 cells which constitutively express NF-Y ([@B123], [@B121]; [@B88]). Nevertheless, it is possible that endogenous NF-Y does not allow maximal Tax-2 transactivation and only its inactivation in cells by the use of dominant-negative NF-Y vectors or by small interfering RNA (siRNA; [@B74]; [@B23]) will provide clear evidence of its negative role in LTR promoter activity.

Several families of proteins binding to the Y-box sequence have been previously identified ([@B67]; [@B129]). Besides NF-YB, two other factors called YB-1 and C/EBPβ have been shown to oppositely regulate HTLV-1 expression. The former increases the basal LTR transcription ([@B55]), the latter, instead, down-regulates Tax-1-mediated transactivation ([@B44]). Thus, distinct family members might exploit alternative mechanisms to modulate HTLV-2 and/or HTLV-1 transcription.

Several chromatin modifying factors, such as Brahma-related gene 1 (BRG1) and histone acetyltransferases (HATs) are commonly used by Tax and CIITA (**Table [1](#T1){ref-type="table"}**). While it is well established that the recruitment of HATs to the 21-bp repeats by Tax plays a critical role in transactivation, it is not clear whether the ATP-dependent chromatin remodeling factor BRG1, also participates in Tax-mediated transactivation. Controversial reports have been published in the past on Tax-1--BRG1 functional interplay. In one study BRG1 was shown to interact with Tax-1 physically and functionally and to enhance its capacity to transactivate LTR promoter ([@B130]; [@B25]). On the contrary, another report indicated that Tax-1-mediated transactivation does not require BRG1 ([@B137]). Interestingly, BRG1 has a dual action on MHC-II gene expression: (i) it induces CIITA pIV promoter activation ([@B90]), (ii) it is recruited by CIITA on MHC-II promoters where, by altering DNA topology, facilitates the access of general transcription factors and coactivators leading to gene expression ([@B81]). Thus the role of BRG1 in the regulation of HTLV-1 replication in presence of CIITA certainly requires further investigation.

The HATs p300, CBP, and PCAF participate with CIITA to the formation of an active MHC-II enhanceosome ([@B57]; [@B32]). Moreover, they also catalyze the acetylation of CIITA at two N-terminal lysine residues within a bipartite nuclear localization signal (NLS). Acetylation or inhibition of deacetylation by Trichostatin A leads to increased nuclear levels of CIITA and higher transactivation of class II genes ([@B115]). Remarkably, CIITA also contains an HAT activity, which is required for IFN-γ-activated MHC-I and MHC-II expression ([@B96]). While the transcriptional activity of CIITA is linked to the recruitment of HATs on class II promoters, histone deacetylation correlates with transcriptional repression and is mediated by distinct histone deacetylase (HDAC) complexes. HDAC1/HDAC2 stably associated with the mSin3A corepressor bind to CIITA and inhibits its transactivating function through a disruption of MHC-II enhanceosome ([@B142]). As far as the involvement of HATs in Tax-mediated HTLV transcription, our studies revealed functional differences among the HAT family members interacting with Tax-1 and Tax-2. In particular, we confirmed that HTLV-1 and HTLV-2 gene transcription is synergistically enhanced by the interaction of CBP/p300 with both Tax-1 and Tax-2. In contrast, Tax-1 but not Tax-2 selectively uses PCAF to optimally transactivate HTLV-1 LTR ([@B123], [@B121]). This effect is independent from the enzymatic activity of PCAF, which might instead engage other coactivators ([@B49]). A selective usage of HATs by the two viral transactivators has been previously demonstrated for the inhibition of p53 by [@B78]. The different requirement for PCAF between Tax-1 and Tax-2 implies that only Tax-1 might affect nuclear PCAF-containing complexes, potentially contributing to the pleiotropic de-regulated expression of cellular genes during T cell transformation. Of note, a reduced transactivation and a defective cellular transformation have been observed with Tax-1 mutants which poorly interact with PCAF ([@B114]; [@B49]). These observations further support the idea that the higher oncogenic potential of Tax-1 with respect to Tax-2 might be, at least in part, attributed to a peculiar utilization of HATs. Similarly to CIITA, Tax-1 interacts with several HDACs including HDAC1, HDAC3, and HDAC6 ([@B127]; [@B63]). HDAC1 binding negatively regulates the HTLV-1 gene expression ([@B27]; [@B65]). Nevertheless, Tax-1 has been shown to replace HDAC1 on LTR promoter allowing transcription initiation ([@B70]). Thus, both CIITA and Tax may act as a molecular switch, to modulate transcription by coordinating the function of both HATs and HDACs. Besides the roles for HATs and HDAC, more recently arginine-specific methylation of histones has emerged as a critical feature for both MHC-II and HTLV-1 transcriptional regulation. The coactivator-associated arginine methyltransferase 1 (CARM1) has been reported to interact and synergize with both CIITA and Tax-1 to optimally activate transcription of their target genes ([@B141]; [@B48]). Aside from their interactions with specific DNA-bound factors and chromatin modifying proteins, Tax and CIITA bind also component of the general transcriptional machinery, such as TFIID, to direct transcription initiation ([@B13]; [@B31]). There is also evidence that both transcription factors recruit the P-TEFb to the target promoters by interacting with the cyclin T1 subunit ([@B53]; [@B138]; [@B18]).

Overall, the findings discussed above highlight the central role of both Tax and CIITA in transcription through the coordination of enhanceosome complex assembly and the control of transcription initiation and elongation.

CIITA EXPLOITS DIFFERENT MOLECULAR MECHANISMS TO INHIBIT THE VIRAL TRANSACTIVATORS Tax-1 AND Tax-2
==================================================================================================

On the basis of what has been described in the previous section, the hypothesis that the physical interaction between CIITA and Tax may solely account for the observed CIITA-mediated inhibition of Tax-dependent LTR transactivation could reflect only part of the complex molecular interplay between the viral and cellular transactivators. Thus, we hypothesized that CIITA might inhibit Tax-mediated transcription also by sequestering one or more of those factors that are commonly used by CIITA and Tax for their specific transcriptional regulatory functions. This idea was further supported by our previous finding that CIITA inhibits HIV-1 replication by competing with Tat for the binding to cyclin T1 of P-TEFb complex ([@B4]). Moreover, it is known that the sequestration of HATs is a common mechanism through which CIITA mediates gene suppression. For instance, CIITA by binding to and sequestering CBP inhibits metalloproteinase-9, collagen α 2(I), thymidine kinase, and cyclin D1 gene expression ([@B140]; [@B86]). In addition, CIITA by competing with NFAT (nuclear factor of activated T-cells) for p300 binding, represses the expression of IL-4 ([@B113]). Similarly, CIITA exerts a repressive effect on Cathepsin E expression most likely via interaction with p300 ([@B135]). For these reasons we assessed whether the over-expression of some of these commonly used factors could rescue Tax function inhibited by CIITA. Whereas the over-expression of HATs did not overcome Tax-2 suppression, the over-expression of PCAF, but not of p300, counteracted the inhibitory function of CIITA on Tax-1 ([@B123], [@B121]). These data imply that CIITA might inhibit the recruitment of PCAF to the transcriptional complex on the viral promoter simply by sequestering it (**Figure [4A](#F4){ref-type="fig"}**). Nevertheless, another possibility is that the intrinsic ability of CIITA to interact with Tax-1, could impair Tax-1--PCAF association (**Figure [3C](#F3){ref-type="fig"}**). Indeed, CIITA decreased the *in vivo* binding of PCAF to Tax-1 ([@B121]). CIITA and PCAF bind to two distinct regions of Tax-1 localized at the N-terminus and at the C-terminus, respectively ([@B49]; [@B121]) indicating that PCAF and CIITA do not compete for the same binding surface of Tax-1. Rather, the binding of CIITA to Tax-1 might alter the conformation of the viral transactivator masking the binding surface to PCAF.

![**Distinct mechanisms account for CIITA-mediated inhibition of HTLV-1Tax-1 and HTLV-2Tax-2.** **(A)** The cellular factors PCAF and CREB/ATF, required for CIITA-mediated MHC-II transcription, are sequestered by CIITA and are no longer available to interact physically and functionally with Tax-1. This results in the inhibition of HTLV-1 LTR transactivation (-). **(B)** CIITA facilitates the interaction between Tax-2 and NF-Y, an inhibitor of Tax-2 transcription function.](fmicb-04-00234-g004){#F4}

Besides PCAF, the over-expression of CREB and ATF1 transcription factors restored CIITA-inhibited Tax-1 transactivation. Because the N-terminal region of Tax-1 interacting with CIITA includes CREB-binding site ([@B130]; [@B121]), it is not surprising that the two factors compete for Tax-1. In the presence of CIITA, CREB might be no longer available for the recruitment of Tax-1 on the 21-bp repeats, thus preventing the assembly of the multiprotein complex required for optimal HTLV-1 LTR transactivation (**Figure [4A](#F4){ref-type="fig"}**).

Overall, these results indicate relevant differences in CIITA-mediated suppression of Tax-1 and Tax-2. The sequestration of HATs is not the major mechanism through which CIITA inhibits Tax-2, which, as discussed above, is functionally suppressed by NF-Y, another essential component of MHC-II enhanceosome. Interestingly, NF-Y cooperates with CIITA to inhibit Tax-2 transactivating function suggesting that CIITA might behave as a bridging factor to assemble a defective Tax-2/CIITA/NF-Y transcriptional complex ([@B123]; **Figure [4B](#F4){ref-type="fig"}**). It has been reported that NF-Y interacts with PCAF ([@B20]) and it is intriguing that the two factors differently affect the transcriptional function of Tax-1 and Tax-2. Tax-1-mediated LTR transcription is enhanced by PCAF, but is not affected by NF-Y. On the contrary, Tax-2-mediated LTR transcription is inhibited by over-expressed NF-Y, but is not increased by PCAF. In this context CIITA seems to exploit the two players to exert its inhibitory function on the viral transactivators by inhibiting the interaction between Tax-1 and its positive coactivator PCAF, while increasing the binding of Tax-2 to its negative regulator NF-Y ([@B88]).

Future efforts will be devoted to assess whether CIITA inhibits Tax by sequestering other commonly used factors or by inhibiting their physical interaction with Tax-1 and/or Tax-2. At the present we can only exclude competition between CIITA and Tax for cyclin T1-binding. Indeed, the region of CIITA mediating Tat suppression differs from that required to inhibit both Tax-1 and Tax-2, indicating that CIITA blocks HIV-1 and HTLVs through different molecular mechanisms (data not shown).

CONCLUSION
==========

In this review we provided an update on the anti-viral features that make CIITA a fundamental link between adaptive and intrinsic immunity against HTLV infections. By inducing MHC-II expression and, thus, antigen presentation, CIITA triggers the activation of TH cells, which, in turn, orchestrate the adaptive immune responses against pathogens. In addition, CIITA has a direct inhibitory effect on the replication of HTLV-1 and HTLV-2 retroviruses by suppressing the transcriptional function of their viral transactivators. CIITA exploits different ways to exert this latter inhibitory function: it binds Tax-1 and Tax-2; it specifically modulates the interaction of Tax-1 and Tax-2 with relevant cellular factors; and it affects the subcellular localization of the two viral transactivators. Thus, CIITA seems to have evolved multiple strategies to be more effective in the inhibition of Tax function. It is known that other host restriction factors may target different steps of viral life cycle to block HIV-1 infection. Nevertheless, the restriction is more effective in species other than the human species, because HIV-1 has developed countermeasures against these innate defenses. In contrast, CIITA is a peculiar restriction factor because restricts HIV-1, HTLV-1, and HTLV-2 in their natural host ([@B4]; [@B14]; [@B121]). So far, no viral products are known to counteract CIITA-mediated restriction. On the contrary, it is well known that some bacteria (e.g., Mycobacteria and Chlamydia) and some viruses (e.g., human cytomegalovirus and Varicella zoster) cause a reduction of MHC-II molecules on the surface of parasitized cells by inhibiting the pathway leading to the activation of CIITA gene transcription ([@B2]). Thus, also HIV-1 and HTLV viruses might have evolved mechanisms to evade the host's immune system based on the suppression of CIITA expression and/or function. At least for HIV-1 infection, our previous results indicated that Tat had no effect on both MHC-II and CIITA expression in T and macrophage cell lines ([@B120]). As far as HTLV-1, it has been reported that Tax-1 increases basal MHC-II transcription by interacting with NF-YB ([@B93]). Moreover, a putative functional effect of Tax-1 on CIITA-mediated MHC-II gene expression, although unlikely, has not been investigated in detail as yet. Future investigation will thus uncover also the possible complementary role that both Tax-1 and Tax-2 might play a role in CIITA-dependent MHC-II transcription.

HTLV-1 and HTLV-2 viruses preferentially infect and replicate in human T lymphocytes, which express MHC-II molecules upon activation. It must be stressed, however, that whereas the expression of MHC-II molecules on the cell surface last for several days, CIITA expression is time-limited because of its very short half-life ([@B105]). Thus, sustained expression of CIITA might be required to control HTLV replication. Interestingly, as discussed above, cell surface MHC-II molecule expression in mature DCs is up-regulated, whereas the expression of CIITA is silenced. This might, at least in part, explain why HTLV-1 productive infection is not counteracted in DCs ([@B51]). These findings disclose the opportunity of developing new therapeutic approaches against HTLV infections based on biological and/or pharmacological strategies aimed at up-regulating, in a controlled manner, the expression of CIITA in cells that are targeted by the virus.

Besides its role as transcriptional activator of HLTV genome transcription, Tax plays a major role in viral pathogenesis and T cell immortalization ([@B39]; [@B102]). Tax deregulates the expression of cellular genes mostly by the constitutive activation of NF-kB pathway and the inhibition of p53 tumor suppressor ([@B92]; [@B66]; [@B72]; [@B79]; [@B91]; [@B95]). It is conceivable that CIITA might exert a broader effect on HTLV infection by counteracting Tax oncogenic potential. Future efforts will be devoted to investigate whether CIITA inhibits Tax-mediated NF-kB activation and p53 suppression.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

This work was supported by the following grants to Roberto S. Accolla: Fondazione Cariplo "Cellular and molecular basis of human retroviral-dependent pathology" (2008--2230); Associazione Italiana Ricerca sul Cancro "New strategies of tumor vaccination and immunotherapy based on optimized triggering of anti-tumor CD4^+^ T cells" (AIRC IG 8862); Italian Ministry of University and Research project PRIN "New strategies of immunointervention against tumors" (2008-WXF7KK); FOCOVA 2012 "New Strategies of Tumor Vaccination and Immunotherapy"; University of Insubria "FAR 2009" and "FAR 2010" to Giovanna Tosi. Rawan Abdallah is a student in the PhD Program of Experimental Medicine and Oncology, University of Insubria, and she is granted by Fondazione Cariplo: Post-graduate Program of Excellence in Innovative Biomedical Technologies 2009-2957. Greta Forlani was supported by University of Insubria and Regione Lombardia Consortium Project DOTE-UNIRE: TumVac, New Strategies of Anti-Tumor Vaccination.

[^1]: Edited by: *Umberto Bertazzoni, University of Verona, Italy*

[^2]: Reviewed by: *Hideki Hasegawa, National Institute of Infectious Diseases, Japan; David W. Brighty, University of Dundee, UK*

[^3]: This article was submitted to Virology, a section of the journal Frontiers in Microbiology.
